New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 25, 2013
07:09 EDTAUXLAuxilium announces primary endpoints met in Xiaflex study
Auxilium announced that new and updated data were presented from its IMPRESS trials, the Phase 3 studies that assessed Xiaflex for the potential treatment of Peyronie's disease. An open-label baseline analysis from IMPRESS 3 showed a mean penile curvature deformity of 53 degrees and a mean PD symptom bother score of 7.3. In this study, both co-primary endpoints of change in PCD and PD symptom bother were met with statistical significance compared to baseline. The mean percent change in PCD was 34.4 percent and the mean change in PD symptom bother score was 3.3 from baseline.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
08:16 EDTAUXLAuxilium management to meet with UBS
Subscribe for More Information
April 11, 2014
07:06 EDTAUXLVIVUS announces avanafil clinical data presentation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use